Clinical-stage biopharmaceutical company Adocia (Euronext Paris:ADOC) announced on Tuesday that it has filed patent applications for stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone platform.
These combinations, such as CagriSema (cagrilintide and semaglutide), can be administered using standard injection devices, offering convenience and flexibility for patients.
Adocia's innovation addresses the challenge of combining different hormones for more effective obesity treatments. By overcoming compatibility issues, Adocia's BioChaperone platform enables the production of stable formulations that can be administered using existing injection devices. This could significantly improve the accessibility and convenience of these treatments.
Adocia is also researching new peptide combinations for obesity treatment and exploring partnerships to advance these innovations.
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing
Implantica publishes real-world data supporting RefluxStop efficacy
Abingdon Health subsidiary awarded GBP500,000 contract
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Humacyte Global receives approval from FDA for Symvess
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US